ABSTRACT
platelet or antithrombotic medications.
1,2 ICAD risk assessment for ischemic complications based on a simple degree of luminal narrowing (percentage stenosis) is imprecise, with complex pathology at the level of the plaque and/or downstream vascular distribution. Several groups have proposed improving patient risk stratification and plaque characterization by using blackblood MR imaging (BBMRI) with high (submillimeter) spatial and contrast resolution to directly analyze the intracranial vessel wall and atherosclerotic plaque. [3] [4] [5] [6] Swartz et al 3 initially reported contrast enhancement of symptomatic ICAD plaques with 3T high-resolution BBMRI; later in a small cohort, they demonstrated qualitatively decreasing enhancement of symptomatic plaques from acute/subacute-to-chronic phases, suggesting plaque inflammation and transient destabilization as an etiology for thromboembolic complications. 4 While ICAD plaque enhancement has been shown to be highly associated with recent cerebrovascular ischemic events, its specificity remains uncertain. Using postcontrast BBMRI, Qiao et al 7 reported observing intracranial plaque enhancement in both culprit (the most stenotic lesion upstream from an ischemic event) and nonculprit lesions in patients with cerebrovascular events. Skarpathiotakis et al 4 reported "strong" ICAD plaque enhancement on postcontrast BBMRI, even 4 months after stroke presentation, and "mild" enhancement as much as 1 year later. The concept of introducing additional quantitative MR imaging parameters by using dynamic contrast-enhanced (DCE) MR imaging to measure adventitial contrast uptake rates, represented by the volume transfer constant (K trans ), was first introduced by Kerwin et al 8 in patients with carotid atherosclerotic disease requiring surgical endarterectomy. These parameters were found to correlate with macrophage infiltration (inflammation) and neovasculature on subsequent histopathologic analysis. [8] [9] [10] In a separate cohort, Dong et al 11 demonstrated that intensive medical management with lipid therapy coincided with a significant decrease in the measured K trans of carotid artery atherosclerosis. In fact, K trans measurements decreased in intervals and responded to medical management with anticholesterolemic (statin) medications during 1 year of therapy, suggesting correlative reduction in neovascularization and/or inflammation, plaque stabilization, and even regression.
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These plaque perfusion parameters may provide information that is also correlated to intracranial plaque inflammation, indicative of both ischemic stroke risk and sensitivity to pharmacologic therapies. Chen et al 12 demonstrated neovascularization in MCA plaques in a postmortem study, suggesting applicability of DCE kinetic modeling to the intracranial vasculature; however, to date, no study has examined the dynamic characteristics of intracranial vessel walls or ICAD plaques using DCE-MR imaging. In this pilot study, we investigated the feasibility of modeling plaque perfusion parameters, fractional plasma volume (V p ), and K trans , using DCE-MR imaging in patients with symptomatic ICAD. We hypothesized that kinetic modeling of the intracranial vessel wall and plaque provide quantitative biomarkers sensitive to time from symptom onset of ICAD, independent of relative T1 signal hyperintensity and post-gadolinium enhancement values as observed on BBMRI.
MATERIALS AND METHODS

Patient Recruitment
Institutional review board approval was obtained for a prospective, Health Insurance Portability and Accountability Act-compliant study of symptomatic patients presenting with ischemic stroke or transient ischemic attack secondary to ICAD with Ͼ50% stenosis and plaques involving the internal carotid artery, A1-A2 anterior cerebral, M1-M2 middle cerebral, and P1-P2 posterior cerebral arteries, or basilar artery (Table 1) . When attributable to the downstream vascular distribution of a single ICAD plaque, "ischemic stroke" was defined as hyperintensity findings on DWI and "TIA" was defined as neurologic deficits that resolved in Ͻ24 hours. Patients were identified and recruited for this study at Northwestern University from March 2013 to May 2015, after receiving a standard clinical head and neck MRI/MRA evaluation, including 3D TOF and DWI sequences. Patients provided consent based on a willingness to participate in a longitudinal study and the ability to undergo a research MR imaging examination within 30 days of the ischemic event.
Recruited patients underwent high-resolution, vessel wall imaging with 3T BBMRI of the intracranial vasculature. In addition, the ICAD stenosis was evaluated with DCE-MR imaging for the purpose of kinetic modeling of permeability (or contrast uptake) into the plaque. Major patient exclusion criteria included complete vessel occlusions, gross patient motion artifacts, susceptibility artifacts from implants, Ͼ50% stenosis of the cervical vasculature or tandem intracranial stenoses (via MRA/CTA or carotid Doppler sonography), cardioembolic risk profile including atrial fibrillation, and standard contraindications to MR imaging (pacemaker, claustrophobia, pregnancy, contrast allergy, or renal insufficiency). We further studied patient demographics, atherosclerotic risk factors, relevant medical management, and clinical presentations using Northwestern University's electronic medical records. 
Imaging Protocol
All patients enrolled in our study were scanned on 3T (Magnetom Trio or Skyra; Siemens, Erlangen, Germany) MR imaging scanners. A 3D TOF MRA sequence was repeated to localize the ICAD plaque in the vessel of interest. The DCE-MR imaging volume was placed to cover the entire segment of the diseased intracranial vessel (Fig 1) with the axis of the vessel aligning with the throughplane direction and in-plane images containing perpendicular vessel cross-sections. Plaque permeability was measured with a standard DCE-MR imaging protocol using a multiphase 3D gradient recalled-echo (GRE)-based pulse sequence. Dynamic volumetric T1-weighted images were acquired approximately every 35 seconds following contrast injection for approximately 10 minutes with the following parameters: flip angle ϭ 10°, TR/TE ϭ 8.7/1.3 ms, matrix ϭ 384 ϫ 384, FOV ϭ 190 -220 mm, and 12 partitions placed to cover the plaque, resulting in voxel dimensions of 0.5 ϫ 0.5 ϫ 2.0 mm. A single dose (0.1 mmol/kg) of T1-shortening gadolinium contrast (gadopentetate dimeglumine, Magnevist; Bayer HealthCare Pharmaceuticals, Wayne, New Jersey) was injected at a rate of 4 mL/s during the DCE acquisition. Precontrast T1 values (T 10 ) of the tissue were determined using a multi-flip angle routine (␣ ϭ 5°, 15°, 25°, 45°) to fit the spoiled gradient-echo signal equation:
3D isotropic, high-resolution BBMRI was performed with T1-weighted TSE sequences, acquired before and immediately after the DCE acquisition (ie, within 20 minutes of the gadolinium injection). A 3D variable flip angle TSE (T1 sampling perfection with application-optimized contrasts by using different flip angle evolution [SPACE]; Siemens) pulse sequence 5, 15 was performed before and after contrast injection with the following parameters: FOV ϭ 165 mm, TR/TE ϭ 800/22 ms, integrated parallel acquisition technique factor ϭ 2, 104 partitions, bandwidth ϭ 372 Hz/pixel, turbo factor ϭ 30, scan time ϳ 8 minutes, voxel volume ϭ 0.5 ϫ 0.5 ϫ 0.6 mm.
Permeability Modeling
The permeability-limited Modified Tofts Model 16 quantifies the kinetics of a tracer leaking through a semipermeable membrane with the following relationship:
with K trans dictating the tracer transfer rate from the intravascular into the extracellular extravascular space (V L ) with units of minute Ϫ1 ; K ep ϭ K trans /V L in units of minute Ϫ1 describing the ratio of the transfer rate (K trans ) to the fractional volume of tracer in the V L ; C p (t), the intravascular tracer concentration; and V p , the fractional plasma volume for each voxel. C(t) is measured adjacent to the patent lumen of the stenotic vessel wall. A Levenberg-Marquardt algorithm was implemented in-house by using a commercially available software prototyping package (Matlab, Version 2014; MathWorks, Natick, Massachusetts) to find the K trans , V L , and V p in Equation 2 that best fit the measured signal C(t). Acquisition of the enhancement curve peak is required for an accurate measurement of V L and may require imaging times greater than 10 minutes. While V L may be related to plaque enhancement, it does not affect the wash-in phase of the enhancement curve 17 ; thus, we restricted our analysis to K trans and V p values as in prior kinetic modeling analyses. 
Data Analysis and Imaging Evaluation
Both DCE and T1 SPACE images were evaluated as a postprocessing step by separate, independent operators who were blinded to both clinical history and the results of complementary image analysis.
T1 SPACE images were analyzed on a Leonardo workstation (Siemens) by a neuroradiologist with Ͼ10 years' experience (A.H.E). Measurements included relative postgadolinium plaque enhancement between pre-and postcontrast imaging, referred to as intraplaque enhancement (IPE), as well as the presence of precontrast signal intensity (SI), referred to as intraplaque hyperintensity (IPH). ROIs were drawn in one section at the site of maximal vessel stenosis, and the mean SI was recorded. ROIs were matched in size and location in the precontrast T1 SPACE dataset. IPE was calculated as SI post Ϫ SI pre / SI pre. Both SI post and SI pre were first normalized to the SI of normal-appearing white matter (NAWM). IPH was measured as the ratio of precontrast plaque SI to extraocular muscle SI.
DCE images were motion-corrected by using the Statistical Parametric Mapping (SPM8 (http://www.fil.ion.ucl.ac.uk/spm/ software/spm12) software package in Matlab (R2014a). The ROI for contrast kinetic analysis was matched as closely as possible to the ROI used for IPE analysis by first coregistering the T1 SPACE postcontrast ROI volumes to DCE-MR imaging volumes and then applying pixel-by-pixel DCE modeling in the section containing maximal plaque enhancement on the coregistered T1 SPACE image. ROIs were drawn in Matlab by a trained operator with Ͼ10 years' experience (P.V.). We evaluated the permeability of the choroid plexus and NAWM [18] [19] [20] in the same patients to provide an internal reference for our plaque contrast kinetic parameters.
Statistical Analysis
We compared quantitative DCE-MR imaging parameters in plaques against the aforementioned independent controls (white matter and choroid plexus) and neuroanatomic structures with differential permeability characteristics. 18, 19, [21] [22] [23] Mean values were compared by using a Student t test with statistical significance defined at the 5% level (P Ͻ .05).
A linear regression analysis was preformed to compare DCE parameters (K trans and V p ) as well as IPH and IPE ratios with the time from symptom onset (in days). Time from symptom onset was calculated as the number of days until DCE and T1 SPACE MR imaging studies were performed at our research institution. This analysis was conducted to evaluate the difference in associativity with time between the 2 imaging markers.
Finally, DCE parameters were compared with IPH and IPE ratios in all plaques by using linear regression to evaluate their interdependent relationships. All statistical analyses were conducted by using built-in statistical software in Matlab. Confidence intervals were set at 95%, and statistical significance was defined at the 5% level (P Ͻ .05).
RESULTS
We evaluated 10 consecutive symptomatic patients (6 men, 4 women; mean age, 58.9 years; range, 39 -70 years) with ICAD plaques by using DCE and TI SPACE MR imaging. Patient demographics, comorbid atherosclerotic risk factors, relevant medical management, and clinical presentations are summarized in Table  1 . In addition, 14 other patients were recruited for scanning but were excluded from this study: 2 with documented complete vessel occlusions in the plaque ROI, 3 with nondiagnostic imaging due to patient motion artifacts, and 9 with confounding tandem or distal plaques in the vessel of interest.
We found a broad-range of K trans and V p values in ICAD plaques ( ; P ϭ 2.3E-06). Similarly, average plaque V p was 18.3% Ϯ 10.2%; range, 5%-40%, and it was significantly smaller than the mean values found in the choroid plexus (mean, 44%; P ϭ 6.8E-06) and larger than mean values measured in NAWM (mean, 1.9%; P ϭ 9.4E-05) (Fig 2) .
Linear regression modeling of DCE plaque permeability parameters and T1 SPACE IPH and IPE ratios demonstrated that K trans was most associated with time from symptom onset in days (r 2 ϭ 0.46, P ϭ .03), but vascular fraction V p (r 2 ϭ 0.12, P ϭ .3), IPH (r 2 ϭ 0.07, P ϭ .47), and IPE (r 2 ϭ 0.005, P ϭ .95) ratios did not correlate significantly (Fig 3) . 
DISCUSSION
In this pilot study, we demonstrated the feasibility of kinetic modeling of contrast uptake in ICAD plaques. Enhancement curve shapes and K trans /V p values were consistent with literature values reported in DCE studies on extracranial carotid plaques 8, 10 and intermediate to values found in the healthy white matter (NAWM) and the choroid plexus. Furthermore, we found that DCE permeability parameters showed little correlation to IPE and IPH values derived from T1 SPACE imaging and demonstrated greater correlation with time from symptom onset. Our findings suggest that contrast kinetics modeled by DCE-MR imaging allows intracranial plaque characterization that differs from preand postcontrast plaque signal or enhancement seen with static vessel wall imaging protocols using BBMRI.
The strong relationship between K trans and time from symptom onset may be evidence of the correlation of contrast kinetics to acute pathophysiologic changes occurring after the destabilization of intracranial plaques and thromboembolic conversion.
Our data did not demonstrate similar temporal correlation with respect to IPE or IPH, consistent with recent intracranial vessel wall imaging studies that showed persistent and strong enhancement in ICAD plaques as much as 6 months after symptom onset. Additional studies that follow symptomatic and asymptomatic plaques longitudinally will be essential to establishing whether contrast uptake rates into the vessel wall provide a more specific and acute measure of plaque stability than static measures of pre-and postcontrast signal or enhancement. Studies by Kerwin et al 8 MR imaging markers to characterize and grade the acute vulnerability of these lesions to thromboembolic/perforator ischemic complications. Even chronic progressing intracranial stenoses may be exacerbated by episodes of plaque inflammation and, in a setting of poor collaterals, could also predispose to hypoperfusion-related ischemic complications irrespective of plaque instability. Differentiating these mechanisms of stroke in ICAD may modulate treatment of symptomatic ICAD in the future, whereby angioplasty/stent placement could be advocated, delayed, or contraindicated in favor of antiplatelets, anticoagulants, statins, or novel anti-inflammatory therapies. Our study has several limitations. First, this pilot study included a relatively small sample size and no longitudinal followup, both of which should be addressed in subsequent studies. Additionally, the patient population was limited to subjects with symptomatic ICAD plaques with Ͼ50% stenosis. Examining asymptomatic plaques and less stenotic lesions, stenoses, which may not be easily characterized by K trans , will be an important subject for future research. Furthermore, the inability to image the plateau and washout phase of plaque contrast prevents accurate estimation of V L . However, this scenario does not preclude accurate measurement of K trans from the wash-in phase of the curve because V L does not affect it. Finally, our model of K trans contrast permeability into the intracranial plaque from the intravascular space to the extracellular extravascular space may be prone to variable mechanisms. Although neovascularization in pathologic ICAD may be a primary mode for plaque permeability/enhancement, passive diffusion from the intraluminal space across a compromised fibrous cap cannot be excluded, and these processes may vary across a spectrum of intracranial plaques.
CONCLUSIONS
We present the results of a prospective pilot study examining the feasibility of kinetic modeling of contrast uptake in ICAD. We demonstrate elevated and variable permeability in symptomatic atherosclerotic plaques (K trans and V p ) less than levels observed in the choroid plexus where an absence of the blood-brain barrier allows intercompartmental tracer exchange. We also found that plaque permeability is more associated with the time from symptom onset than IPE or IPH ratios as measured on BBMRI via T1 SPACE vessel wall imaging. Coupled with the fact that neither K trans nor V p strongly correlated with IPE or IPH, these findings suggest that permeability modeling of plaque contrast kinetics may provide a new imaging biomarker for ICAD plaque instability.
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